Effective testosterone suppression for patients with prostate cancer: Is there a best castration?

Urology

Volumn 62, Issue 2, 2003, Pages 207-213

  Oefelein, Michael G ^a   Resnick, Martin I ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ALENDRONIC ACID; AMINOGLUTETHIMIDE; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; DIETHYLSTILBESTROL; ESTROGEN; FLUTAMIDE; GONADORELIN; LEUPRORELIN; NILUTAMIDE; TESTOSTERONE; ZOLEDRONIC ACID;

BONE DENSITY; BONE MINERAL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; GYNECOMASTIA; HEALTH CARE COST; HEART INFARCTION; HORMONE ACTION; HUMAN; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SIDE EFFECT; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0043125563     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00331-5     Document Type: Review

References (49)

1. Carcinoma of the prostate treatment comparisons . J Urol. 98:1967;516-522.
2. Byar D.P. The Veterans Administration Cooperative Urological Research Group's study of cancer of the prostate. Cancer. 32:1973;1126-1130.
3. Leo M.E., Bilhartz D.L., Bergstralh E.J., et al. Prostate specific antigen in hormonally treated D2 prostate cancer is it always an accurate indicator of disease status? J Urol. 145:1991;802-806.
4. Kaisary A.V., Tyrrell C.J., Peeling W.B., et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostate cancer. Br J Urol. 67:1991;502-508.
5. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 311:1984;1281-1286.
6. Chang A., Yeap B., Davis T., et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma flutamide versus diethylstilbestrol . J Clin Oncol. 14:1996;2250-2257.
7. Navratil H. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin results of 49 cases from a multicentre study . Prog Clin Biol Res. 243A:1987;401-410.
8. Eisenberger M.A., Crawford E.D., Wolf M., et al. Prognostic factors in stage D2 prostate cancer important implications for future trials - results of a cooperative intergroup study (INT 0036) . Semin Oncol. 21:1994;613-619.
9. Crawford D., Faulkner J., Thompson I.M., et al. Ten-year survival in patients with metastatic (M+) prostate cancer (CAP) analysis of Southwest Oncology Group (SWOG) 8894 . J Urol. 167:2002;304a.
10. Oefelein M.G., Ricchiuti V., Conrad P.W., et al. Clinical predictors of androgen-independent prostate cancer and survival in the prostate specific antigen era. Urology. 60:2002;120-124.
11. Maximum androgen blockade in advanced prostate cancer a overview of the randomised trials . Lancet. 355:2000;1474-1475.
12. Hedlund P.O., Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma effects on overall survival and cardiovascular mortality. The Scandinavian Prostate Cancer Group (SPCG)-5 trial study . Urology. 55:2000;328-333.
13. Scherr D., Pitts W.R., Vaughan E.D. Diethylstilbestrol revisited androgen deprivation, osteoporosis and prostate cancer . J Urol. 167:2002;535-538.
14. Dearnaley D.P., Sydes M.R. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer first results of the MRC Pr05 trial . Proc Am Soc Clin Oncol. 20:2001;174a.
15. Berruti A., Dogliotti L., Tucci M., et al. Metabolic bone disease induced by prostate cancer rationale for the use of bisphosphonates . J Urol. 166:2001;2023-2031.
16. Agency for Health Care Policy and Research: Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer. AHCPR Publication No. 99-E0012. Available at: http://www.ahcpr.gov. Accessed January 2003.
17. Trachtenberg J., Gittleman M., Steidle C., et al. A phase III multicenter, open label randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol. 167:2002;1670-1674.
18. Geller J., Albert J.D. DHT in prostate cancer tissue a guide to management and therapy . Prostate. 6:1985;19-25.
19. Labrie F., Veillux R., Fournier A. Low androgen levels induce the development of androgen-hypersensitive cell clones Shionogi mouse mammary carcinoma cells in culture. J Natl Cancer Inst. 80:1988;1138-1147.
20. Iversen P. A randomized comparison of bicalutamide (Casodex) 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer first report from the Scandinavian Prostatic Cancer Group Study 6 . Eur Urol. 42:2002;204-211.
21. See W.A., Wirth M.P., McLeod D.G., et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer first analysis of the Early Prostate Cancer Program . J Urol. 168:2002;429-435.
22. Schmitt B., Wilt T.J., Schellhamer P.F., et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer a systemic review . Urology. 57:2001;727-732.
23. Eisenberger M.A., Walsh P.C. Early androgen deprivation for prostate cancer? N Engl J Med. 341:1999;1837-1838.
24. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet. 124:1967;1011-1017.
25. Byar D., Corle D.K. Hormone therapy for prostate cancer results of the Veterans Administration Cooperative Urologic Research Group studies . Natl Cancer Inst Monogr. 7:1988;165-170.
26. Jordan W.P. Jr, Blackard C.E., Byar D.P. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J. 70:1977;1411-1413.
27. Kent J.R., Bischoff A.J., Arduino L.J. Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. J Urol. 109:1973;858-860.
28. Immediate versus deferred treatment for advanced prostatic cancer initial results of the Medical Research Council trial . Br J Urol. 79:1997;235-246.
29. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 341:1999;1781-1788.
30. Ghavamian R., Bergstralh E.J., Blute M.L., et al. Radical retropubic prostatectomy plus orchiectomy alone for pTxN+prostate cancer a matched comparision . J Urol. 161:1999;1223-1228.
31. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) a phase III randomized trial . Lancet. 360:2002;103-106.
32. Oefelein M.G. Quality of life utilizing the serum testosterone to redose LH-RH agonists. J Urol. 169:2003;251-255.
33. Oefelein M.G., Feng A., Scolieri M.J., et al. A reassessment of the definition of castrate levels of testosterone implications for clinical decision making . Urology. 56:2000;1021-1024.
34. Shearer R.J., Hendry W.F., Sommerville I.F., et al. Plasma testosterone an accurate monitor of hormone treatment in prostate cancer . BJU Int. 45:1973;668-673.
35. Oefelein M.G., Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone-releasing hormone agonist therapy the case for monitoring serum testosterone levels and a treatment decision algorithm . J Urol. 164:2000;726-769.
36. Kawakami J., Morales A. A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonists. J Urol. 167:2002;288a.
37. Hurtado-Coll A., Goldenberg S.L., Gleave M.E., et al. Intermittent androgen suppression in prostate cancer the Canadian experience . Urology. 60:2002;52-56.
38. Millikan R., Logothetics C. National Comprehensive Cancer Network (NCCN) Practice Guidelines version 1.97. Oncology. 11:1997;180-201.
39. Sabbatini P., Larson S.M., Kremer A., et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 17:1999;948-957.
40. Albertsen P.C., Fryback D.G., Storer B.E., et al. Long-term survival of conservatively treated localized prostate cancer. JAMA. 274:1995;626-631.
41. De Voogt H.J., Suciu S., Sylvester R. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer results from 2 European Organization for Research on Treatment of Cancer trials . J Urol. 141:1989;883-888.
42. Chodak G.W., Volgelzang N.J., Caplan R.J., et al. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA. 265:1991;618-621.
43. Walsh P.C. Hormonal therapy for prostatic carcinoma. Urol Clin North Am. 2:1975;125-140.
44. Ockrim J.L., Lalani E.N., Laniado M.E., et al. Transdermal estrogen therapy for advanced prostate cancer - forward to the past? J Urol. 167:2002;175a.
45. Lukkarinen O., Hammond G.L., Kontturi M., et al. Testicular steroid secretion and peripheral serum steroid concentrations in patients with prostatic carcinoma after short-term estrogen treatment. Invest Urol. 16:1979;453-456.
46. Fowler J.E., Gottesman J.E., Reid C.F., et al. Safety and efficacy of an implantable leuprolide delivery system for patients with advanced prostate cancer. J Urol. 164:2000;730-734.
47. Chu F.M., Jayson M., Dineen M.K., et al. A clinical study of 22.5 mg LA-2550 a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer . J Urol. 168:2002;1199-2004.
48. Hellman L., Bradlow H.L., Levin F.J., et al. The effect of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins. J Clin Endocrinol Metab. 45:1977;1224-1229.
49. Trachtenberg J., Pont A. Ketoconazole in the treatment of metastatic prostatic cancer. Lancet. 2:1984;433-440.